B+L Introduces Chewable Vitamin
Bausch + Lomb has introduced PreserVision AREDS 2 Formula Chewable vitamins, designed especially for individuals who have swallowing difficulties, in a mixed-berry flavor. A daily dose of one in the morning and one in the evening offers patients 500mg vitamin C, 400IU vitamin E, 80mg zinc, 2mg copper, 10mg lutein and 2mg zeaxanthin. PreserVision AREDS 2 Formula Chewable vitamins are expected to be available for purchase at major retailers this month.


B+L also launches LUMIFY
B+L also has launched LUMIFY(brimonidine tartrate 0.025%), an over-the-counter eyedrop for the treatment of eye redness. LUMIFY is an alpha-2-adrenergic receptor agonist that selectively constricts venules but maintains the availability of oxygen to surrounding tissue. It is available at major retailers in 2.5ml and 7.5ml sizes. Eye Therapies, Inc., licensed the solution to B+L or its affiliates. For information, call 800.828.9030, or go to or


J&J’s Andy Chatbot Answers Contact Lens Questions
Johnson & Johnson Vision has introduced Andy, a virtual assistant chatbot powered by artificial intelligence, to help patients considering contact lenses for the first time or long-term wearers throughout their ACUVUE Brand Contact Lens journey. Andy allows users to get answers to their contact lens-related questions from their computers or mobile devices and provides intuitive coaching to help new wearers develop healthy contact lens habits. Andy can be found by connecting with ACUVUE on the Facebook Messenger app, which is available for free download from the App Store or Google Play store. Call 800.843.2020, or go to

New Mask Relieves Dry Eye Symptoms
Heyedrate has released a dry eye mask that is now available on Amazon. The mask serves as a soothing compress for dry eyes, blepharitis, meibomian gland dysfunction, headaches, allergies and sinuses. The patient warms the mask in the microwave for 15 to 20 seconds and then applies the warm compress over closed eyes for 15 to 20 minutes to alleviate discomfort caused by dry eyes, itching, crusts on the eyelids, sensitivity to light, and irritation, to name a few symptoms. Patients also can chill the mask for a minimum of two hours and use it as a cold compress for 15 minutes to relieve sinus headaches and allergies. The mask is washable by hand and can be reused. Go to

Glow-in-the-Dark Contact Lens Could Prevent Diabetic Blindness
California Institute of Technology student Colin Cook and a group of Caltech researchers have developed a glow-in-the-dark contact lens they say may help prevent vision loss in individuals with diabetic retinopathy. The lenses aim to reduce the metabolic demands of the retina, namely the retina’s night-time oxygen demand. To do so, the lens gives the rod cells the faintest amount of light to look at while the wearer sleeps. “If we turn metabolism in the retina down, we should be able to prevent some of the damage that occurs,” Cook said.

The illumination is provided by tiny vials filled with tritium, a radioactive form of hydrogen gas that emits electrons, which are then converted into light by a phosphorescent coating. This system ensures a constant light output for the lifetime of the contact lens.

The vials are implanted in the lens in a radial pattern, creating a circle that is just big enough to fall outside of the wearer’s view when the pupils are constricted in lighted conditions. In the dark, the pupil expands, and the faint glow from the vials can illuminate the retina. The contact lens design also ensures that the retina receives an appropriate dose of light throughout the night.

Early testing shows that rod cell activity is reduced by as much as 90% when worn in the dark. In the next few months, Cook and his fellow researchers plan to start testing the lenses to see if their ability to reduce retinal metabolism will translate into the prevention of diabetic retinopathy. Following those tests, they will seek FDA permits to begin clinical trials. Go to

Novartis’ FocalView App Aids Researchers
Novartis has launch its FocalView app, an ophthalmic digital research platform, to allow researchers to track disease progression by collecting real-time, self-reported data directly from consenting patients. By adapting the design of clinical trials to suit the daily routine of patients, the app may reduce barriers to participation, according to the company. FocalView aims to help patients complete various assessments, gaining feedback on their visual function, including any changes over time. At the same time, the app could provide researchers with a greater volume of real-world, patient-reported data, creating more flexible and accessible clinical trial designs.
Novartis plans to test FocalView in a prospective, non-interventional study to evaluate the app’s efficacy and usability in assessing visual function. These measurements include visual acuity and contrast sensitivity. Researchers will, in turn, assess ease of use, level of enrollment and the ability to obtain important documentation for future clinical trial research, such as informed consent. In the next phase, the app will be validated against traditional visual testing that takes place within conventional clinical settings.

FocalView is now available for download from the App Store in the U.S. Consent to contribute to research data will be required before a user can interact with the tool. Go to

MaximEyes EHR Software Given Health IT Certification
MaximEyes EHR software (Version 3.0) from First Insight Corporation, has received 2015 Edition Health IT Certification from the Office of the National Coordinator for Health Information Technology (ONC-Health IT). The certification enables clinicians to use the software to meet requirements for value-based care programs from the Centers for Medicare and Medicaid. These include the Merit-Based Incentive Payment System (MIPS), Alternative Payment Models (APMs), and the Medicaid EHR incentive program.

MaximEyes EHR was tested and certified through the Drummond Group LLC, an ONC-Authorized Certification Body and has been certified in accordance with the applicable certification criteria adopted by the Secretary of Health and Human Services. Call 800.920.1940, or go to


Leave A Reply